FNIH has selected CRI to be its source of landscape intelligence in immuno-oncology.
Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.
A comprehensive, neutral analysis of the global cancer cell therapy landscape; 753 cancer cell therapies in the global development pipeline, with 375 in clinical studies
30 days of education and awareness programming for patients, caregivers, and the public about cancer immunotherapy and clinical trials
Cancer Research Institute iAtlas Poised to Improve Patient Outcomes by Providing Researchers Greater Access to Genomics Data
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
An interview with bestselling author Charles Graeber about his new book, The Breakthrough: Immunotherapy and the Race to Cure Cancer.
Dr. Jill O’Donnell-Tormey participated in an expert panel discussion on rare cancers for The Forum at the Harvard T.H. Chan School of Public Health in February 2019.